Trial Outcomes & Findings for A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part A: Japanese Participants (P05956) (NCT NCT00591409)
NCT ID: NCT00591409
Last Updated: 2019-03-01
Results Overview
Neuromuscular functioning was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from neuromuscular blockade (NMB). In this study, twitch responses were recorded until the T4/T1 Ratio reached \>= 0.9, the minimum acceptable ratio that indicated recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.9 indicates a faster recovery from NMB.
Recruitment status
COMPLETED
Study phase
PHASE2
Target enrollment
100 participants
Primary outcome timeframe
Day 1: From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.9 (up to 24 hours)
Results posted on
2019-03-01
Participant Flow
Japanese participants who had a surgical procedure using a general anesthesia of rocuronium or vecuronium for endotracheal intubation and maintenance of neuromuscular block were enrolled in this study.
Participant milestones
| Measure |
Rocuronium + Placebo
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Rocuronium + 0.5 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Rocuronium + 1.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 2.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 4.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
Vecuronium + Placebo
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Vecuronium + 0.5 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Vecuronium + 1.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 2.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 4.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
10
|
10
|
10
|
10
|
10
|
10
|
10
|
10
|
9
|
11
|
|
Overall Study
Treated
|
10
|
10
|
10
|
10
|
9
|
10
|
10
|
10
|
9
|
10
|
|
Overall Study
COMPLETED
|
10
|
10
|
10
|
10
|
9
|
10
|
10
|
10
|
9
|
10
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
1
|
Reasons for withdrawal
| Measure |
Rocuronium + Placebo
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Rocuronium + 0.5 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Rocuronium + 1.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 2.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 4.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
Vecuronium + Placebo
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Vecuronium + 0.5 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Vecuronium + 1.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 2.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 4.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
Not Treated
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
1
|
Baseline Characteristics
A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part A: Japanese Participants (P05956)
Baseline characteristics by cohort
| Measure |
Rocuronium + Placebo
n=10 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Rocuronium + 0.5 mg/kg Sugammadex
n=10 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Rocuronium + 1.0 mg/kg Sugammadex
n=10 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 2.0 mg/kg Sugammadex
n=10 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 4.0 mg/kg Sugammadex
n=9 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
Vecuronium + Placebo
n=10 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Vecuronium + 0.5 mg/kg Sugammadex
n=10 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Vecuronium + 1.0 mg/kg Sugammadex
n=10 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 2.0 mg/kg Sugammadex
n=9 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 4.0 mg/kg Sugammadex
n=10 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
Total
n=98 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Continuous
|
41 Years
STANDARD_DEVIATION 10 • n=5 Participants
|
44 Years
STANDARD_DEVIATION 10 • n=7 Participants
|
49 Years
STANDARD_DEVIATION 9 • n=5 Participants
|
45 Years
STANDARD_DEVIATION 10 • n=4 Participants
|
41 Years
STANDARD_DEVIATION 15 • n=21 Participants
|
49 Years
STANDARD_DEVIATION 14 • n=8 Participants
|
49 Years
STANDARD_DEVIATION 8 • n=8 Participants
|
46 Years
STANDARD_DEVIATION 13 • n=24 Participants
|
52 Years
STANDARD_DEVIATION 13 • n=42 Participants
|
44 Years
STANDARD_DEVIATION 14 • n=42 Participants
|
46 Years
STANDARD_DEVIATION 12 • n=42 Participants
|
|
Sex: Female, Male
Female
|
5 Participants
n=5 Participants
|
7 Participants
n=7 Participants
|
5 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
7 Participants
n=21 Participants
|
6 Participants
n=8 Participants
|
5 Participants
n=8 Participants
|
6 Participants
n=24 Participants
|
5 Participants
n=42 Participants
|
3 Participants
n=42 Participants
|
54 Participants
n=42 Participants
|
|
Sex: Female, Male
Male
|
5 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
5 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
4 Participants
n=8 Participants
|
5 Participants
n=8 Participants
|
4 Participants
n=24 Participants
|
4 Participants
n=42 Participants
|
7 Participants
n=42 Participants
|
44 Participants
n=42 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
10 Participants
n=5 Participants
|
10 Participants
n=7 Participants
|
10 Participants
n=5 Participants
|
10 Participants
n=4 Participants
|
9 Participants
n=21 Participants
|
10 Participants
n=8 Participants
|
10 Participants
n=8 Participants
|
10 Participants
n=24 Participants
|
9 Participants
n=42 Participants
|
10 Participants
n=42 Participants
|
98 Participants
n=42 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
PRIMARY outcome
Timeframe: Day 1: From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.9 (up to 24 hours)Population: All randomized participants who received sugammadex or placebo; without any protocol violations, and who had at least one post baseline efficacy measurement, who had a TOF trace, had a reliable TOF trace, and where drug administration did not interfere with the effect of rocuronium or vecuronium.
Neuromuscular functioning was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from neuromuscular blockade (NMB). In this study, twitch responses were recorded until the T4/T1 Ratio reached \>= 0.9, the minimum acceptable ratio that indicated recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.9 indicates a faster recovery from NMB.
Outcome measures
| Measure |
Rocuronium + Placebo
n=6 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Rocuronium + 0.5 mg/kg Sugammadex
n=5 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Rocuronium + 1.0 mg/kg Sugammadex
n=10 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 2.0 mg/kg Sugammadex
n=7 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 4.0 mg/kg Sugammadex
n=9 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
Vecuronium + Placebo
n=7 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Vecuronium + 0.5 mg/kg Sugammadex
n=3 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Vecuronium + 1.0 mg/kg Sugammadex
n=8 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 2.0 mg/kg Sugammadex
n=6 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 4.0 mg/kg Sugammadex
n=10 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Time From Start of Administration of Sugammadex or Placebo to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9
|
82.08 Minutes
Standard Deviation 27.57
|
3.95 Minutes
Standard Deviation 2.50
|
2.48 Minutes
Standard Deviation 1.28
|
2.17 Minutes
Standard Deviation 1.23
|
1.85 Minutes
Standard Deviation 1.17
|
83.20 Minutes
Standard Deviation 20.63
|
52.03 Minutes
Standard Deviation 64.92
|
10.63 Minutes
Standard Deviation 19.23
|
2.77 Minutes
Standard Deviation 0.83
|
2.08 Minutes
Standard Deviation 0.90
|
SECONDARY outcome
Timeframe: Day 1: From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.7 (up to 24 hours)Population: All randomized participants who received sugammadex or placebo; without any protocol violations, and who had at least one post baseline efficacy measurement, who had a TOF trace, had a reliable TOF trace, and where drug administration did not interfere with the effect of rocuronium or vecuronium.
Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.7 indicates a faster recovery from NMB.
Outcome measures
| Measure |
Rocuronium + Placebo
n=7 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Rocuronium + 0.5 mg/kg Sugammadex
n=5 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Rocuronium + 1.0 mg/kg Sugammadex
n=10 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 2.0 mg/kg Sugammadex
n=9 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 4.0 mg/kg Sugammadex
n=9 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
Vecuronium + Placebo
n=9 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Vecuronium + 0.5 mg/kg Sugammadex
n=4 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Vecuronium + 1.0 mg/kg Sugammadex
n=9 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 2.0 mg/kg Sugammadex
n=8 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 4.0 mg/kg Sugammadex
n=10 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Time From Start of Administration of Sugammadex or Placebo to Recovery of the T4/T1 Ratio to 0.7
|
52.60 Minutes
Standard Deviation 16.27
|
2.35 Minutes
Standard Deviation 0.70
|
1.73 Minutes
Standard Deviation 0.85
|
1.23 Minutes
Standard Deviation 0.38
|
1.20 Minutes
Standard Deviation 0.27
|
85.85 Minutes
Standard Deviation 75.12
|
12.52 Minutes
Standard Deviation 17.95
|
2.87 Minutes
Standard Deviation 1.13
|
2.30 Minutes
Standard Deviation 0.60
|
1.33 Minutes
Standard Deviation 0.43
|
SECONDARY outcome
Timeframe: Day 1: From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.8 (up to 24 hours)Population: All randomized participants who received sugammadex or placebo; without any protocol violations, and who had at least one post baseline efficacy measurement, who had a TOF trace, had a reliable TOF trace, and where drug administration did not interfere with the effect of rocuronium or vecuronium.
Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.8 indicates a faster recovery from NMB.
Outcome measures
| Measure |
Rocuronium + Placebo
n=6 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Rocuronium + 0.5 mg/kg Sugammadex
n=5 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Rocuronium + 1.0 mg/kg Sugammadex
n=10 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 2.0 mg/kg Sugammadex
n=9 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 4.0 mg/kg Sugammadex
n=9 Participants
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
Vecuronium + Placebo
n=7 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Vecuronium + 0.5 mg/kg Sugammadex
n=3 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Vecuronium + 1.0 mg/kg Sugammadex
n=9 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 2.0 mg/kg Sugammadex
n=8 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 4.0 mg/kg Sugammadex
n=10 Participants
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Time From Start of Administration of Sugammadex or Placebo to Recovery of the T4/T1 Ratio to 0.8
|
63.67 Minutes
Standard Deviation 21.77
|
2.70 Minutes
Standard Deviation 1.00
|
1.87 Minutes
Standard Deviation 0.98
|
1.50 Minutes
Standard Deviation 0.55
|
1.32 Minutes
Standard Deviation 0.35
|
68.40 Minutes
Standard Deviation 19.58
|
5.55 Minutes
Standard Deviation 1.90
|
3.75 Minutes
Standard Deviation 1.45
|
3.08 Minutes
Standard Deviation 1.68
|
1.63 Minutes
Standard Deviation 0.48
|
Adverse Events
Rocuronium + Placebo
Serious events: 0 serious events
Other events: 10 other events
Deaths: 0 deaths
Rocuronium + 0.5 mg/kg Sugammadex
Serious events: 0 serious events
Other events: 10 other events
Deaths: 0 deaths
Rocuronium + 1.0 mg/kg Sugammadex
Serious events: 0 serious events
Other events: 10 other events
Deaths: 0 deaths
Rocuronium + 2.0 mg/kg Sugammadex
Serious events: 1 serious events
Other events: 9 other events
Deaths: 0 deaths
Rocuronium + 4.0 mg/kg Sugammadex
Serious events: 0 serious events
Other events: 8 other events
Deaths: 0 deaths
Vecuronium + Placebo
Serious events: 0 serious events
Other events: 10 other events
Deaths: 0 deaths
Vecuronium + 0.5 mg/kg Sugammadex
Serious events: 1 serious events
Other events: 9 other events
Deaths: 0 deaths
Vecuronium + 1.0 mg/kg Sugammadex
Serious events: 0 serious events
Other events: 9 other events
Deaths: 0 deaths
Vecuronium + 2.0 mg/kg Sugammadex
Serious events: 0 serious events
Other events: 9 other events
Deaths: 0 deaths
Vecuronium + 4.0 mg/kg Sugammadex
Serious events: 0 serious events
Other events: 9 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Rocuronium + Placebo
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Rocuronium + 0.5 mg/kg Sugammadex
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Rocuronium + 1.0 mg/kg Sugammadex
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 2.0 mg/kg Sugammadex
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 4.0 mg/kg Sugammadex
n=9 participants at risk
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
Vecuronium + Placebo
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Vecuronium + 0.5 mg/kg Sugammadex
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Vecuronium + 1.0 mg/kg Sugammadex
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 2.0 mg/kg Sugammadex
n=9 participants at risk
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 4.0 mg/kg Sugammadex
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Gastrointestinal disorders
Swollen tongue
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Infections and infestations
Intrauterine infection
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Gastrointestinal disorders
Glossodynia
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
Other adverse events
| Measure |
Rocuronium + Placebo
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Rocuronium + 0.5 mg/kg Sugammadex
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Rocuronium + 1.0 mg/kg Sugammadex
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 2.0 mg/kg Sugammadex
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Rocuronium + 4.0 mg/kg Sugammadex
n=9 participants at risk
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
Vecuronium + Placebo
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
|
Vecuronium + 0.5 mg/kg Sugammadex
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
Vecuronium + 1.0 mg/kg Sugammadex
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 2.0 mg/kg Sugammadex
n=9 participants at risk
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
Vecuronium + 4.0 mg/kg Sugammadex
n=10 participants at risk
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Injury, poisoning and procedural complications
Postoperative fever
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Injury, poisoning and procedural complications
Postoperative wound complication
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
44.4%
4/9 • Number of events 6 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
20.0%
2/10 • Number of events 3 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Injury, poisoning and procedural complications
Procedural hypertension
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Injury, poisoning and procedural complications
Procedural hypotension
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Injury, poisoning and procedural complications
Procedural pain
|
80.0%
8/10 • Number of events 8 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
70.0%
7/10 • Number of events 7 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
70.0%
7/10 • Number of events 7 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
60.0%
6/10 • Number of events 7 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
88.9%
8/9 • Number of events 8 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
90.0%
9/10 • Number of events 9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
70.0%
7/10 • Number of events 7 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
90.0%
9/10 • Number of events 9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
55.6%
5/9 • Number of events 5 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
80.0%
8/10 • Number of events 8 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Injury, poisoning and procedural complications
Wound secretion
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Investigations
Albumin urine present
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Injury, poisoning and procedural complications
Anxiety postoperative
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Injury, poisoning and procedural complications
Endotracheal intubation complication
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Injury, poisoning and procedural complications
Incision site haemorrhage
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Injury, poisoning and procedural complications
Mental status changes postoperative
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Injury, poisoning and procedural complications
Peripheral nerve injury
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Injury, poisoning and procedural complications
Post procedural complication
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Injury, poisoning and procedural complications
Post procedural haemorrhage
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Injury, poisoning and procedural complications
Post procedural oedema
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Cardiac disorders
Palpitations
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Ear and labyrinth disorders
Ear pain
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Ear and labyrinth disorders
Tinnitus
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Eye disorders
Conjunctival hyperaemia
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Eye disorders
Corneal oedema
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Eye disorders
Eye discharge
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Eye disorders
Eye pain
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Eye disorders
Eye swelling
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Gastrointestinal disorders
Abdominal discomfort
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Gastrointestinal disorders
Anal fistula
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Gastrointestinal disorders
Cheilitis
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Gastrointestinal disorders
Constipation
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Gastrointestinal disorders
Diarrhoea
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Gastrointestinal disorders
Gingival swelling
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Gastrointestinal disorders
Glossodynia
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Gastrointestinal disorders
Hypoaesthesia oral
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Gastrointestinal disorders
Intra-abdominal haemorrhage
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Gastrointestinal disorders
Mouth haemorrhage
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Gastrointestinal disorders
Nausea
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
40.0%
4/10 • Number of events 4 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
40.0%
4/10 • Number of events 4 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
40.0%
4/10 • Number of events 4 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
44.4%
4/9 • Number of events 4 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
40.0%
4/10 • Number of events 4 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
50.0%
5/10 • Number of events 6 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
40.0%
4/10 • Number of events 5 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
55.6%
5/9 • Number of events 5 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Gastrointestinal disorders
Oral discomfort
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Gastrointestinal disorders
Palatal oedema
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Gastrointestinal disorders
Stomatitis
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Gastrointestinal disorders
Swollen tongue
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Gastrointestinal disorders
Toothache
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
22.2%
2/9 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
20.0%
2/10 • Number of events 3 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
30.0%
3/10 • Number of events 3 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
22.2%
2/9 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
General disorders
Application site erythema
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
General disorders
Application site pruritus
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
General disorders
Catheter site haemorrhage
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
General disorders
Catheter site pain
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
General disorders
Chest pain
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
General disorders
Chills
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
General disorders
Discomfort
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
General disorders
Face oedema
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
General disorders
Feeling abnormal
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
General disorders
Gait disturbance
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
General disorders
Infusion site erythema
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
General disorders
Infusion site mass
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
General disorders
Injection site pain
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
General disorders
Instillation site pain
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
General disorders
Instillation site reaction
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
General disorders
Lower extremity mass
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
General disorders
Malaise
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
General disorders
Oedema
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
General disorders
Peripheral coldness
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
General disorders
Puncture site pain
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
General disorders
Pyrexia
|
40.0%
4/10 • Number of events 4 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
30.0%
3/10 • Number of events 3 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
50.0%
5/10 • Number of events 5 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
30.0%
3/10 • Number of events 3 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
33.3%
3/9 • Number of events 3 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
50.0%
5/10 • Number of events 5 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
40.0%
4/10 • Number of events 4 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
44.4%
4/9 • Number of events 4 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
General disorders
Thirst
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
General disorders
Venipuncture site swelling
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Infections and infestations
Cystitis
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Infections and infestations
Herpes simplex
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Infections and infestations
Nasopharyngitis
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Infections and infestations
Oral infection
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Infections and infestations
Pneumonia mycoplasmal
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Injury, poisoning and procedural complications
Agitation postoperative
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Injury, poisoning and procedural complications
Anaesthetic complication cardiac
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Investigations
Beta 2 microglobulin increased
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Investigations
Beta 2 microglobulin urine increased
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Investigations
Blood pressure decreased
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Investigations
Blood pressure increased
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Investigations
Blood urine present
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Investigations
Body temperature decreased
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Investigations
C-reactive protein increased
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Investigations
Gamma-glutamyltransferase increased
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Investigations
Haematocrit decreased
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Investigations
Haemoglobin decreased
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Investigations
Red blood cells urine positive
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Investigations
Urine output decreased
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Investigations
White blood cell count increased
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Investigations
White blood cells urine positive
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Metabolism and nutrition disorders
Anorexia
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Metabolism and nutrition disorders
Dehydration
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
30.0%
3/10 • Number of events 3 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
30.0%
3/10 • Number of events 3 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
20.0%
2/10 • Number of events 3 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
33.3%
3/9 • Number of events 3 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc protrusion
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Musculoskeletal and connective tissue disorders
Sensation of heaviness
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Musculoskeletal and connective tissue disorders
Spinal osteoarthritis
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Nervous system disorders
Dizziness
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
30.0%
3/10 • Number of events 4 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Nervous system disorders
Headache
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
30.0%
3/10 • Number of events 3 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Nervous system disorders
Hypoaesthesia
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
22.2%
2/9 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Nervous system disorders
Intracranial hypotension
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Nervous system disorders
Nystagmus
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Nervous system disorders
Peroneal nerve palsy
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Nervous system disorders
Sensory disturbance
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Nervous system disorders
Trigeminal palsy
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Psychiatric disorders
Insomnia
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
20.0%
2/10 • Number of events 3 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Psychiatric disorders
Tension
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Renal and urinary disorders
Dysuria
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Renal and urinary disorders
Pollakiuria
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Reproductive system and breast disorders
Genital pruritus female
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Reproductive system and breast disorders
Pelvic pain
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Reproductive system and breast disorders
Vulval erythema
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Respiratory, thoracic and mediastinal disorders
Dysphonia
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Respiratory, thoracic and mediastinal disorders
Haemoptysis
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Respiratory, thoracic and mediastinal disorders
Laryngeal oedema
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Respiratory, thoracic and mediastinal disorders
Nasal discomfort
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Respiratory, thoracic and mediastinal disorders
Pharyngeal erythema
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Respiratory, thoracic and mediastinal disorders
Pharyngolaryngeal discomfort
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Respiratory, thoracic and mediastinal disorders
Pharyngolaryngeal pain
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
30.0%
3/10 • Number of events 3 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
33.3%
3/9 • Number of events 3 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
20.0%
2/10 • Number of events 2 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory disorder
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Respiratory, thoracic and mediastinal disorders
Rhinalgia
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Respiratory, thoracic and mediastinal disorders
Rhinitis allergic
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Respiratory, thoracic and mediastinal disorders
Tracheal pain
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Skin and subcutaneous tissue disorders
Blister
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Skin and subcutaneous tissue disorders
Dermatitis contact
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Skin and subcutaneous tissue disorders
Haemorrhage subcutaneous
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Skin and subcutaneous tissue disorders
Petechiae
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Skin and subcutaneous tissue disorders
Seborrhoeic dermatitis
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Skin and subcutaneous tissue disorders
Skin erosion
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Skin and subcutaneous tissue disorders
Subcutaneous emphysema
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Skin and subcutaneous tissue disorders
Swelling face
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
11.1%
1/9 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Vascular disorders
Haematoma
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Vascular disorders
Orthostatic hypotension
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
|
Vascular disorders
Pallor
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
10.0%
1/10 • Number of events 1 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/9 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
0.00%
0/10 • Up to 7 days after sugammadex or placebo treatment
All participants as treated
|
Additional Information
Senior Vice President, Global Clinical Development
Merck Sharp & Dohme Corp.
Phone: 1-800-672-6372
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee Any scientific paper, presentation, or other communication concerning this clinical trial will first be submitted to the Sponsor, at least six weeks ahead of estimated publication or presentation, for written consent, which shall not be withheld unreasonably.
- Publication restrictions are in place
Restriction type: OTHER